Unlock this StockReport nowClick to Unlock

Cellmid Share Price

CDY A$0.215 0.0  0.0%

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 30th Jun 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg
Revenue A$m
Operating Profit A$m
Net Profit A$m
EPS Reported AUD¢
EPS Normalised AUD¢
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps AUD¢
Capex ps AUD¢
Free Cashflow ps AUD¢
Dividend ps AUD¢
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc A$m
Working Capital A$m
Net Fixed Assets A$m
Net Debt A$m
Book Value A$m
Average Shares m
Book Value ps AUD¢ -27.6%

FINANCIAL BRIEF: For the six months ended 31 December 2018, Cellmid Limited revenues increased 12% to A$3.6M. Net loss increased from A$1.1M to A$3.5M. Revenues reflect Sales Revenue increase of 13% to A$3.5M, Interest received increase from A$20K to A$49K, Other Revenue increase from A$2K to A$10K. Higher net loss reflects Professional fees expense increase from A$489K to A$2.2M (expense), Employee benefits expense increase of 18% to A$1.8M (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score  
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Dec '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
30th Jun 2019
30th Jun 2020

Price Target: A$1.06
(+3931% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (A$) (¢) (¢) (A$) (¢) (¢)
Consensus Estimate
1m Change
3m Change
1 broker Broker Consensus Trend
Broker Recommendations for Cellmid
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 1 0

Named Brokers and Analysts
Blue Ocean Equities Micheal Gerges ,

Profile Summary

Cellmid Limited develops and markets therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The Company operates in two segments: research and development of diagnostics and therapeutics, and research, development and marketing of hair growth products. It develops and commercializes diagnostic and therapeutic products for the management of diseases, such as cancer and various chronic inflammatory conditions by targeting midkine (Midkine Businesses, Lyramid and Kinera), and the development and sale of over-the-counter (OTC) treatments to alleviate excessive and abnormal hair loss, and re-establish the natural hair growth cycle (Consumer Health Business). Its products include Midkine ELISA kit; Advangen International hair loss products, and Evolis products, which are a range of hair growth products. The Company, through its subsidiaries, develops and sells treatments for various forms of hair loss (alopecia).

Directors: Maria Halasz (CEO) , Lee Tamplin (SEC) , David King (NEC) , Martin Cross (NED) , Dennis Eck (NED) 73, Bruce Gordon (NED) , Edward Walton (NED) ,

No. of Employees: n/a No. of Shareholders: n/a

Last Annual June 30th, 2018
Last Interim December 31st, 2018
Incorporated October 8, 2004
Public Since December 9, 2005
Shares in Issue 84,108,592
Free Float 65.6m (78.0%)
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Australian Stock Exchange - SEATS
Eligible for an ISA? a SIPP?

CDY Share Price Performance CDY Share Price Quote
0.0  0.0%
Traded 1:00am · Minimum 15 min delayed · NMS:

Latest CDY News Announcements (delayed)

Upcoming CDY Events

Recent ↓
Friday 7th September, 2018
Cellmid Ltd Extraordinary Shareholders Meeting
Monday 27th February, 2017
Interim 2017 Cellmid Ltd Earnings Release
Tuesday 24th January, 2017
Cellmid Ltd KPI Quarterly Report - December 2016
Thursday 21st April, 2016
Cellmid Ltd KPI Quarterly Report - March 2016
Thursday 25th February, 2016
Interim 2016 Cellmid Ltd Earnings Release
Thursday 25th February, 2016
Interim 2016 Cellmid Ltd Earnings Call
Wednesday 27th January, 2016
Cellmid Ltd KPI Quarterly Report - December 2015
Thursday 12th November, 2015
Cellmid Ltd Annual Shareholders Meeting
Tuesday 27th October, 2015
Cellmid Ltd KPI Quarterly Report - September 2015
Monday 31st August, 2015
Preliminary 2015 Cellmid Ltd Earnings Release
Wednesday 5th August, 2015
Cellmid Ltd Secondary Public Offering Pricing
Thursday 30th July, 2015
Cellmid Ltd KPI Quarterly Report - June 2015

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.

Should you buy CDY

Access CDY Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis